A detailed history of Acadian Asset Management LLC transactions in Alector, Inc. stock. As of the latest transaction made, Acadian Asset Management LLC holds 740,235 shares of ALEC stock, worth $1.38 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
740,235
Previous 590,662 25.32%
Holding current value
$1.38 Million
Previous $2.68 Million 28.57%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$4.34 - $6.58 $649,146 - $984,190
149,573 Added 25.32%
740,235 $3.45 Million
Q2 2024

Aug 06, 2024

BUY
$4.19 - $6.23 $611,802 - $909,673
146,015 Added 32.84%
590,662 $2.68 Million
Q1 2024

May 10, 2024

BUY
$5.69 - $8.08 $1.72 Million - $2.44 Million
301,936 Added 211.57%
444,647 $2.68 Million
Q4 2023

Feb 13, 2024

SELL
$3.77 - $8.39 $39,792 - $88,556
-10,555 Reduced 6.89%
142,711 $1.14 Million
Q3 2023

Nov 13, 2023

BUY
$5.2 - $8.77 $323,206 - $545,099
62,155 Added 68.22%
153,266 $993,000
Q2 2023

Aug 07, 2023

BUY
$5.86 - $7.93 $474,372 - $641,941
80,951 Added 796.76%
91,111 $547,000
Q1 2023

May 11, 2023

SELL
$5.85 - $9.84 $540,850 - $909,737
-92,453 Reduced 90.1%
10,160 $62,000
Q4 2022

Feb 14, 2023

SELL
$6.88 - $9.55 $547,771 - $760,351
-79,618 Reduced 43.69%
102,613 $943,000
Q3 2022

Nov 14, 2022

BUY
$8.19 - $13.2 $698,230 - $1.13 Million
85,254 Added 87.91%
182,231 $1.73 Million
Q2 2022

Aug 09, 2022

BUY
$7.65 - $14.24 $484,413 - $901,705
63,322 Added 188.15%
96,977 $985,000
Q1 2022

May 12, 2022

SELL
$13.02 - $20.78 $94,941 - $151,527
-7,292 Reduced 17.81%
33,655 $478,000
Q4 2021

Feb 10, 2022

BUY
$19.35 - $25.54 $792,324 - $1.05 Million
40,947 New
40,947 $843,000

Others Institutions Holding ALEC

About Alector, Inc.


  • Ticker ALEC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,563,904
  • Market Cap $154M
  • Description
  • Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...
More about ALEC
Track This Portfolio

Track Acadian Asset Management LLC Portfolio

Follow Acadian Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.